Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
July 06 2020 - 7:00AM
Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the
“
Corporation”)
, a clinical stage
immuno-oncology company developing innovative therapies for the
treatment of cancer, announced the voting results from its Annual
and Special Meeting of Shareholders (the
“
Meeting”) held on June 30, 2020.
The results of the director elections were as follows:
Name |
Votes in Favor |
% Votes in Favor |
Votes Withheld |
% Votes Withheld |
Mr. Luke Beshar |
40,277,008 |
99.9 |
52,069 |
0.1 |
Dr. Robert Kirkman |
40,274,992 |
99.9 |
54,085 |
0.1 |
Dr. Thomas Reynolds |
39,850,295 |
98.8 |
478,782 |
1.2 |
Dr. Jan Skvarka |
40,288,126 |
99.9 |
40,951 |
0.1 |
Dr. Helen Tayton-Martin |
40,309,723 |
99.9 |
19,354 |
<0.1 |
Mr. Paul Walker |
40,301,058 |
99.9 |
28,019 |
0.1 |
The shareholders of the Corporation also voted
to reappoint Ernst & Young LLP, Chartered Professional
Accountants, Licensed Public Accountants as auditors of the
Corporation for the ensuing year. In addition, the disinterested
shareholders approved the 2020 omnibus equity incentive plan. For
complete voting results on all matters approved at the Meeting,
please see the Corporation’s Report of Voting Results dated July 6,
2020 available on SEDAR at www.sedar.com.
“Dr. Calvin Stiller and Dr. Michael Moore
elected to retire from the board and did not stand for reelection
this year,” said Dr. Robert Kirkman, Chair of the Board of
Directors of Trillium Therapeutics. “We wish to thank Dr. Stiller
and Dr. Moore for the leadership and guidance which they have
provided to Trillium for many years. We wish all the best for them
in their future endeavors.”
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative
therapies for the treatment of cancer. The Company’s two clinical
programs, TTI-621 and TTI-622, target CD47, a “do not eat me”
signal that cancer cells frequently use to evade the immune
system.
For more information visit:
www.trilliumtherapeutics.com
Company Contact:James
ParsonsChief Financial OfficerTrillium Therapeutics Inc.
416-595-0627 x232james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Media Relations:Mike Beyer Sam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2023 to Aug 2024